Race Oncology (ASX:RAC) received approval from the Bellberry Human Research Ethics Committee to start its RC220 Phase 1 clinical trial at Gosford and Wyong hospitals in New South Wales, according to a Monday filing with the Australian bourse.
The clinical research organization now expects to obtain final site approvals and activation by April, the filing said. Patient enrollment will start once these approvals are received. Human ethics approval for additional trial sites in Australia, Hong Kong, and South Korea is expected in the coming months.
The RAC-010 clinical trial aims to assess the safety, tolerability, and pharmacokinetics of RC220 alone and in combination with doxorubicin in patients with solid tumors, the filing stated.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。